Navigation Links
Joint Center for Cancer Precision Medicine established
Date:11/12/2013

BOSTONThe Joint Center for Cancer Precision Medicine, a collaborative initiative among Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and the Broad Institute of MIT and Harvard, has been established to create "precision medicine treatment pathways" for patients with advanced cancers and to speed the development of personalized therapies.

The Joint Center brings together expertise and resources in state-of-the-art capabilities including DNA sequencing and other tumor molecular profiling technologies, pathology, radiology, surgery, computational interpretation, and new tumor model systems; and reinforces the joint commitment to pursue advances in cancer genetics to improve patient care. It will be headquartered at Dana-Farber.

"This center will allow us to be optimally positioned to answer the big questions in cancer genetics, especially as they affect clinical decision-making," said Levi Garraway, MD, PhD, associate professor of medicine at Dana-Farber and the new center's director. "We seek to understand which genetic and other molecular alterations predict how tumors will respond to targeted drugs, why some patients become resistant to drugs, and what that means about the treatments that should be tried next."

"Our mission is to accelerate the development of personalized therapies that achieve long-term disease control and, eventually, the cure of many patients with advanced cancer," Garraway said. The terms "precision" and "personalized" both refer to an emerging form of cancer care that identifies genetic changes within a patient's tumor that can be used to predict how it will behave and which drugs will be most effective against it.

"The center is creating a new capability to use these huge resources in sequencing and pathology and making sure the data gets to caregivers to help customize treatment," said Edward Benz, Jr., MD, president of Dana-Farber.

"This excit
'/>"/>

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute
Source:Eurekalert  

Page: 1 2 3 4

Related medicine news :

1. Joint-Replacement Failure Rate Higher for Smokers: Studies
2. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
3. Obesity, Diabetes May Raise Complications After Joint Replacement
4. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
5. Joint Replacement Boosts Heart Attack Risk Right After Surgery: Study
6. Joint Commission certifies 2 Primary Stroke Centers at Penn Medicine
7. Joint EACPR and AHA statement empowers health care professional to use Clinical Cardiopulmonary Exercise Testing
8. No proof that patients lose weight after joint replacement surgery
9. Topical Products for Muscle, Joint Pain May Cause Burns: FDA
10. Toward a better material for hip replacement and other joint implants
11. Obese Children Struggle With Joint Pain: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Joint Center for Cancer Precision Medicine established
(Date:1/22/2015)... 2015 The U.S. Pharmacopeial Convention is ... of Clinical Pharmacy Services at North Carolina State’s College ... the 2015 Beal Award for Distinguished Volunteer Service—the organization’s ... on the contributions of volunteer experts to direct its ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Osteotech, Inc.,(Nasdaq: OSTE ), a global ... musculoskeletal system, announced today that Sam Owusu-Akyaw,Osteotech,s President ... Albany Capital,s Regenerative Technologies Conference in New York.,Mr. ... Eastern Time on,Tuesday, September 11, 2007. Osteotech, ...
... undergone previous heart surgery, Belgian study finds , , MONDAY, Sept. ... tiny openings significantly reduces the risk of death for people ... "We were astonished that the reduction in risk was much ... staff surgeon at the OLV Clinic in Aalst and lead ...
... Sponsorship will provide support for ADA,s Por Tu Familia ... Association (ADA) today announced that Goya Foods, Inc. has ... outreach program, Por Tu,Familia. Por Tu Familia (or "for ... about the seriousness of diabetes,and the importance of a ...
... NEW YORK, Sept. 10 portionpals(R), the fastest ... reached the quarter million,sales mark with no national ... operation. "Our sales are coming strictly from word-of-mouth," ... September 9th, Jamie Moose,of Manistique, Michigan became our ...
... choices , MONDAY, Sept. 10 (HealthDay News) -- U.S. and ... a comprehensive recommendation on how much of what types of ... diets. , Both the American Dietetic Association and the Dietitians ... that 20 percent to 30 percent of energy needs should ...
... Broad Street, LANSDOWNE, Va., Sept. 10 ... by former Philadelphia,Eagle and now pastor Herbert Lusk, ... Christ to bring the women of Philadelphia much ... targeting an,area of downtown Philadelphia, where there are ...
Cached Medicine News:Health News:Small Incisions Make Heart Valve Surgery Safer 2Health News:Small Incisions Make Heart Valve Surgery Safer 3Health News:American Diabetes Association and Goya Foods Inc. Team Up To Support Diabetes Awareness and Outreach in the Latino Community 2Health News:American Diabetes Association and Goya Foods Inc. Team Up To Support Diabetes Awareness and Outreach in the Latino Community 3Health News:Experts Sort Out Good Fats From Bad 2Health News:Women of Philadelphia Win by a 'Touchdown' 2
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)...  BiOptix is pleased to announce the appointment of Dr. ... and Biochemistry. Scott joins the company after previous scientific leadership ... the course of his nearly 20 year career in ... nationally recognized thought leader in the biosensor field and ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... to Eye via,Ophthalmic Artery, WASHINGTON, March 17 ... retinoblastoma -- a,deadly, inherited cancer of one or ... from having their eyes surgically removed (enucleated),according to ... the Society of,Interventional Radiology,s 33rd Annual Scientific Meeting. ...
... investigational regimen demonstrates important role of, radioimmunotherapy in ... ... remissions, SEATTLE, March 17 Cell Therapeutics, ... that patients with previously,untreated follicular non-Hodgkin,s lymphoma (NHL) ...
Cached Medicine Technology:New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 2New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 3New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 4Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 2Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 3Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 4
Standard reading test. 'It was the month of May'...
Standard reading test. "Clearing weather..."...
The PowerLab 4/25T is an integrated data recording unit featuring built-in amplifiers. With appropriate transducers and accessories the PowerLab 4/25T covers the broad experimental requirements in li...
Near PT test card/Tumbling E, tumbling hands 5 1/2" X 8"....
Medicine Products: